Next Article in Journal
Acknowledgment to Reviewers of Scientia Pharmaceutica in 2020
Previous Article in Journal
Porophyllum Genus Compounds and Pharmacological Activities: A Review
Open AccessArticle

Development and Validation of a Rapid Analytical Method for the Simultaneous Quantification of Metabolic Syndrome Drugs by HPLC-DAD Chromatography

School of Engineering and Sciences, Department of Sciences, Tecnologico de Monterrey, Campus Monterrey, Ave. Eugenio Garza Sada 2501 Sur, Monterrey, NL C.P. 64849, Mexico
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2021, 89(1), 8; https://doi.org/10.3390/scipharm89010008
Received: 17 December 2020 / Revised: 29 December 2020 / Accepted: 30 December 2020 / Published: 21 January 2021
Worldwide, 25% of the population suffers from metabolic syndrome (MetS). The treatment of patients with MetS regularly includes drugs prescribed simultaneously to treat several disorders that manifest at the same time, such as hypercholesterolemia, arterial hypertension, and diabetes. To the authors’ best knowledge, there is no previous published analytical method for the simultaneous quantification of drugs used in the treatment of these diseases. In the present study, a rapid high-performance liquid chromatography with a diode-array detector HPLC-DAD methodology was developed for simultaneous quantification of carvedilol (CVD), telmisartan (TEL), bezafibrate (BZT), gliclazide (GZD), and glimepiride (GMP) in bulk and pharmaceutical form. The chromatographic separation of the five pharmaceuticals was achieved on a Hypersil GOLD C18 Selectivity (5 µm, 150 × 4.60 mm2) using a mobile phase of acetonitrile (50%) and 0.02 M KH2PO4, pH 3 (50%) at a flow rate of 1 mL/min and at 25 °C. The total separation time was 9 min. The analytical method was validated following the International Conference on Harmonization guidelines. A reproducible method was obtained with acceptable limits of detection (LOD) and quantification (LOQ) for CVD (0.012 and 0.035 μg mL−1), TEL (0.103 and 0.313 μg mL−1), BZT (0.025 and 0.076 μg mL−1), GZD (0.039 and 0.117 μg mL−1), and GMP (0.064 and 0.127 μg mL−1). The validated method allowed the determination of these drugs in commercial pharmaceutical products both individually and simultaneously. The present method was found to be suitable for simultaneous quantification of the five drugs that are most commonly used in the simultaneous treatment of the metabolic syndrome. View Full-Text
Keywords: reversed-phase HPLC; separation; quantification; metabolic syndrome; carvedilol; telmisartan; bezafibrate; gliclazide; glimepiride; drug reversed-phase HPLC; separation; quantification; metabolic syndrome; carvedilol; telmisartan; bezafibrate; gliclazide; glimepiride; drug
Show Figures

Graphical abstract

MDPI and ACS Style

Cruz-Angeles, J.; Martínez, L.M.; Videa, M.; Rodríguez-Rodríguez, J.; Martínez-Jiménez, C. Development and Validation of a Rapid Analytical Method for the Simultaneous Quantification of Metabolic Syndrome Drugs by HPLC-DAD Chromatography. Sci. Pharm. 2021, 89, 8. https://doi.org/10.3390/scipharm89010008

AMA Style

Cruz-Angeles J, Martínez LM, Videa M, Rodríguez-Rodríguez J, Martínez-Jiménez C. Development and Validation of a Rapid Analytical Method for the Simultaneous Quantification of Metabolic Syndrome Drugs by HPLC-DAD Chromatography. Scientia Pharmaceutica. 2021; 89(1):8. https://doi.org/10.3390/scipharm89010008

Chicago/Turabian Style

Cruz-Angeles, Jorge; Martínez, Luz M.; Videa, Marcelo; Rodríguez-Rodríguez, José; Martínez-Jiménez, Cecilia. 2021. "Development and Validation of a Rapid Analytical Method for the Simultaneous Quantification of Metabolic Syndrome Drugs by HPLC-DAD Chromatography" Sci. Pharm. 89, no. 1: 8. https://doi.org/10.3390/scipharm89010008

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop